Nexcella
Phase 1The NEXICART-2 clinical trial is dedicated to evaluating the safety and efficacy of our investigational CAR-T cell therapy (NXC-201) for patients with
Founded
2022
Focus
Cell & Gene Therapy
About
The NEXICART-2 clinical trial is dedicated to evaluating the safety and efficacy of our investigational CAR-T cell therapy (NXC-201) for patients with
Funding History
2Total raised: $65M
Series A$50MMubadala CapitalJun 15, 2023
Seed$15MVida VenturesSep 15, 2021
Company Info
TypePrivate
Founded2022
LocationHouston, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile